Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of diet-drug developer Arena Pharmaceuticals (NAS: ARNA) were tipping the scales today, gaining as much as 53% in intraday trading after the company's flagship drug was approved by the U.S. Food and Drug Administration.
So what: It's been 13 years since the FDA approved a diet drug, but Arena's Belviq has ended the drought. The regulator gave Belviq the go-ahead for treatment of patients with a body-mass index (BMI) of 27 or greater, which covers those classified as overweight and obese. Patients also have to have a condition associated with their weight, such as high blood pressure or type 2 diabetes.
Now what: Since an FDA advisory panel had given Arena's drug a thumbs-up back in May, the FDA's decision shouldn't come as a complete surprise to investors. However, there's been a particularly high bar for getting diet drugs through the approval process -- just ask Arena competitors VIVUS (NAS: VVUS) and Orexigen (NAS: OREX) -- so the final approval was hardly a slam dunk.
What there's little question of at this point is the size of the potential market for Belviq. But with the approval now in the bank, the next big hurdle for investors is how receptive the market will be and how quickly Arena and its marketing partner Eisai can ramp up sales.
Want to keep up to date on these stocks?
The article Why Arena Pharmaceuticals' Shares Jumped originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.Fool contributorMatt Koppenhefferhas no financial interest in any of the companies mentioned. You can check out what Matt is keeping an eye on by visiting hisCAPS portfolio, or you can follow Matt on Twitter,@KoppTheFool, or onFacebook. The Fool'sdisclosure policyprefers dividends over a sharp stick in the eye.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.